Chronic Myelogenous Leukemia
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) | BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| FDA (1) | ABL1 p.T315I, BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| FDA (2) HC (2) | BCR::ABL1 | Chronic Myelogenous Leukemia | Bosutinib | |
| FDA (3) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| FDA (2) HC (2) | BCR::ABL1 | Chronic Myelogenous Leukemia | Imatinib | |
| FDA (3) | BCR::ABL1 | Chronic Myelogenous Leukemia | Nilotinib | |
| FDA (1) HC (1) | ABL1 p.T315I | Chronic Myelogenous Leukemia | Ponatinib |